JO
RAPP

John Overdeck’s Rapport Therapeutics RAPP Stock Holding History

John Overdeck’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Sell
24,470
-3,633
-13% -$134K ﹤0.01% 3603
2026
Q1 		$879K Sell
28,103
-22,516
-44% -$633K ﹤0.01% 3357
2025
Q4 		$1.54M Buy
50,619
+29,119
+135% +$806K ﹤0.01% 2641
2025
Q3 		$639K Buy
21,500
+1,757
+9% +$31.3K ﹤0.01% 2868
2025
Q2 		$224K Sell
19,743
-14,014
-42% -$149K ﹤0.01% 2877
2025
Q1 		$339K Buy
+33,757
New +$438K ﹤0.01% 2667
2024
Q3 		– Sell
-13,000
Closed -$302K – 3380
2024
Q2 		$302K Buy
+13,000
New +$301K ﹤0.01% 2592

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

John Overdeck's RAPP Position: Q2 2026 in Review

John Overdeck reduced its Rapport Therapeutics (RAPP) stake by 13% in Q2 2026, selling an estimated $134K and leaving 24,470 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3603.

John Overdeck first reported a position in RAPP in Q2 2024 and has held it in 7 quarters since. The position peaked at $1.54M in Q4 2025. 159 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • John Overdeck held 24,470 shares of Rapport Therapeutics worth $1.02M as of Q2 2026.
  • John Overdeck sold 3,633 Rapport Therapeutics shares in Q2 2026, an estimated $134K.
  • Rapport Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3603 holding.
  • John Overdeck first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • John Overdeck's Rapport Therapeutics position peaked at $1.54M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.